RxDoctor Payments Data

Erin Kiley

Family · Madison Heights, MINPI 1720748767

Payments from drug & device makers

$5,597in general payments, 2019–2025

Across 316 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$602
  • Alkermes, Inc.$538
  • Corium, LLC$434
  • USWM, LLC$242
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$5,53899%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,597 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$16,581
Medicare patients
31
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl50$67,907
Bupropion XlBupropion Hcl60$989
Buspirone Hcl36$388
Lamotrigine35$383
Aripiprazole24$295
Trazodone Hcl38$287
Duloxetine Hcl19$284
Venlafaxine Hcl ErVenlafaxine Hcl25$277
Quetiapine Fumarate24$275
Escitalopram Oxalate29$245
Fluticasone Propionate18$212
Hydroxyzine Hcl34$194
Paroxetine Hcl23$144
Ibuprofen12$142
Sertraline Hcl30$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,442$67,90750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Madison Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →